Improving CAR T-cell persistence
V Pietrobon, LA Todd, A Goswami, O Stefanson… - International journal of …, 2021 - mdpi.com
Over the last decade remarkable progress has been made in enhancing the efficacy of CAR
T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in …
T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in …
Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?
SJ Abi-Aad, J Zouein, A Chartouni, N Naim… - …, 2023 - Taylor & Francis
Immunotherapy has improved the prognosis of many cancers, yet a large number of patients
have demonstrated resistance to current immune checkpoint inhibitors. LAG-3 is an immune …
have demonstrated resistance to current immune checkpoint inhibitors. LAG-3 is an immune …
Proteomic profiling of advanced melanoma patients to predict therapeutic response to anti-PD-1 therapy
Purpose: Despite high clinical need, there are no biomarkers that accurately predict the
response of patients with metastatic melanoma to anti-PD-1 therapy. Experimental Design …
response of patients with metastatic melanoma to anti-PD-1 therapy. Experimental Design …
Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota
Immunotherapies are recently emerged as a new strategy in treating various kinds of
cancers which are insensitive to standard therapies, while the clinical application of …
cancers which are insensitive to standard therapies, while the clinical application of …
[HTML][HTML] Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1
AS Vickram, SI Shofia, A Saravanan… - EXCLI …, 2024 - pmc.ncbi.nlm.nih.gov
The emergence of checkpoint inhibitors targeting the PD-1/PD-L1 axis marks a paradigm
shift in cancer therapy, offering a novel avenue for enhancing patient outcomes. This review …
shift in cancer therapy, offering a novel avenue for enhancing patient outcomes. This review …
Immunotherapy revisited
T Füreder - memo-Magazine of European Medical Oncology, 2021 - Springer
For melanoma patients a 5-year overall survival (OS) rate of 52% was reported upon
administration of dual CPI therapy with ipilimumab plus nivolumab [4]. Despite promising …
administration of dual CPI therapy with ipilimumab plus nivolumab [4]. Despite promising …